492 Views | 379 Downloads
CORRESPONDENCE Scott E. Hensley: shensley@wistar.org
Author contributions: S.E. Hensley, P.C. Wilson, R. Ahmed, T.M. Ross, S. Esposito, N. Principi, and J. Wrammert designed and supervised experiments. Y. Li, J.L. Myers, C.B. Sullivan., J. Madara, S.L. Linderman, D.M. Carter, and J. Wrammert performed experiments.
D.L. Bostick and J.B. Plotkin completed computational modeling.
Q. Liu and Y. Li completed statistical analyses.
S.E. Hensley and Y. Li wrote the paper with input from all authors.
R. Ahmed., J. Wrammert, and P.C. Wilson have a licensing agreement with MedImmune on the influenza virus-specific human monoclonal antibodies.
There are no further conflicting financial interests.
S.E. Hensley is supported by the NIH (NIAID K22AI091651), the state of PA CURE funds, the Wistar Institute Cancer Center Core grant, and a University of Pennsylvania Institute for Translational Medicine and Therapeutics grant.
J.B. Plotkin and D.L. Bostick are supported by the Burroughs Wellcome Fund, the David and Lucile Packard Foundation, the James S. McDonnell Foundation, the Alfred P. Sloan Foundation, and a University of Pennsylvania Institute for Translational Medicine and Therapeutics grant.
D.L. Bostick is also supported by the NIH (NIH T32A1055400).
J. Madara is supported by the Penn Genome Frontiers Institute. T.M. Ross is supported by the NIH (NIAID GM083602-01).
D.M. Carter is supported by an Oak Ridge Visiting Scientist training program award.
Computational support from the San Diego Supercomputing Center is gratefully acknowledged.
We acknowledge support from Jeffrey Faust and the Wistar Institute Flow Cytometry Facility.
This work used the Extreme Science and Engineering Discovery Environment (XSEDE), which is supported by National Science Foundation grant number OCI-1053575.
© 2013 Li et al.